SITE SPECIFIC DATA ITEMS (SSDI)/ GRADE

Description

Post Transplant Lymphoproliferative Disorder (PTLD) is a lymphoid proliferation arising in a recipient of a solid organ transplant, allogeneic bone marrow transplantation, or an umbilical cord blood transfusion. The patient must have a history of a solid organ transplant or an allogeneic bone marrow transplant. Both polymorphic and monomorphic PTLD are actually caused by post-transplant immunosuppression. Most cases of PTLD occur within a year of transplantation; however, they can occur any time after the transplant. Monomorphic PTLD may have histology indistinguishable from that of various malignant hematopoietic neoplasms, particularly lymphomas such as Diffuse Large B-cell Lymphoma.

Notes

**Note 1:** **Effective years** * This SSDI is effective for diagnosis years 2025+ * For cases diagnosed 2018-2024, this SSDI must be blank **Note 2:** **Definition of PTLD** * Post Transplant Lymphoproliferative Disorder (PTLD) is a lymphoid proliferation arising in a recipient of a solid organ transplant, allogeneic bone marrow transplantation, or an umbilical cord blood transfusion. * The development of PTLD is clinically significant and a prognostic indicator * See the Hematopoietic database for more information **Note 3:** **Types of PTLD** * **Polymorphic PTLD**: This is a PTLD by itself, there is no accompanying lymphoma, plasmacytoma or other type of Hematopoietic neoplasm. This type of PTLD is NOT collected in this data item. * **Monomorphic PTLD (Code 1)**: This is the most common PTLD and is associated with a malignant hematopoietic neoplasm. Most common, but not limited to, diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma * **(Classic Hodgkin lymphoma-PTLD type (Code 2)**: Under the microscope, Reed-Sternberg cells, which are associated with Hodgkin lymphoma are present * **PTLD, NOS (Code 4)**: Used when only PTLD (NOS) is documented and there is no mention of monomorphic or Hodgkin like type